International Stem Cell Corp. (ISCO)

[axelvento]

SS:

Series B Convertible Preferred stock, $0.001 par value, 5,000,000 shares authorized, 250,000
issued and outstanding, with liquidation preferences of $402 and $396 at June 30, 2018
and December 31, 2017, respectively


—



—

Series D Convertible Preferred stock, $0.001 par value, 50 shares authorized, 43 issued and
outstanding, with liquidation preference of $4,320


—



—

Series G Convertible Preferred stock, $0.001 par value, 5,000,000 shares authorized,
issued and outstanding, with liquidation preference of $5,000


5



5

Series I-1 Convertible Preferred stock, $0.001 par value, 2,000 shares authorized, 1,094 and
1,304 issued and outstanding, with liquidation preferences of $1,094 and $1,304 at
June 30, 2018 and December 31, 2017, respectively







Series I-2 Convertible Preferred stock, $0.001 par value, 4,310 shares authorized,
issued and outstanding with liquidation preference of $4,310







Common stock, $0.001 par value, 120,000,000 shares authorized, 6,295,888 and 6,057,132
shares issued and outstanding at June 30, 2018 and December 31, 2017,



"Six patients have now fully completed the study and entered the follow-up phase while two other patients have completed the six-month evaluation. The treatment phase of the study will conclude following the dosing of the last two patients of the third cohort, which ISCO plans to complete soon."

The surgery, which was performed by a team of neurosurgeons at the Royal Melbourne Hospital in Melbourne, Australia, proceeded without complications and the patient was discharged soon after.

https://www.thermh.org.au/